On 6 February 2018 the Minister of Health, Social Services and Equality met with the Spinal Muscular Atrophy Foundation to present that the first treatment for spinal muscular atrophy (SMA) will be financed within the National Health System. SMA is an orphan designated disease that is estimated to affect between 300 and 400 patients in Spain.
The drug (Spinraza®) will be available for use from March 1 with Spain, together with Italy, being one of the first countries in Europe to include this drug in pharmaceutical services.
The Spanish Ministry of Health has launched a new model for the treatment of ultra-rare diseases with high economic and health impact with Spinraza® being the first drug approved.
Please click here to read the full press release.
To read more about market access in Spain please click here.